Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Autologous Platelet-rich Plasma Versus Whole Blood for Epidural Patch in Spontaneous Intracranial Hypotension

22 maj 2026 uppdaterad av: Fang Luo, Beijing Tiantan Hospital

Autologous Platelet-rich Plasma Versus Whole Blood for Epidural Patch in Spontaneous Intracranial Hypotension: A Multi-center, Prospective, Randomized Controlled Trial

Spontaneous intracranial hypotension (SIH) is a condition characterized by refractory orthostatic headache, mostly due to leaks of cerebrospinal fluid (CSF). Epidural patch with autologous platelet-rich plasma (PRP), which contains numerous growth factors and cytokines, has been reported as a new and promising alternative for current standard whole blood patching. However, there is no study comparing the efficacy and safety of the two approaches. In this study, we aimed to provide data concerning the outcomes of PRP patching versus conventional whole blood patching for treatment of refractory SIH cases failing in conservative therapy.

Studieöversikt

Status

Har inte rekryterat ännu

Studietyp

Interventionell

Inskrivning (Beräknad)

218

Fas

  • Inte tillämpbar

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Barn
  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Beskrivning

Inclusion Criteria:

  • Informed consent to participate the research obtained from the patient
  • Satisfies the criteria for SIH according to the International Classification of Headache Disorders.

Exclusion Criteria:

  • There was concern for other causes of intracranial hypotension, such as postdural puncture, postsurgical and post-traumatic CSF leaks
  • Prior treatment with EBP at any time previously
  • Any contraindication to epidural puncture, such as space-occupying intracranial or intraspinal lesions, spinal defect, suspected infection over the puncture site, bleeding disorder and current anticoagulation therapy
  • History of drug and alcohol abuse, cognitive dysfunction, or mental illness
  • Unable to cooperate with postoperative evaluation, treatment, rehabilitation, and follow-up visits

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Enda

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: PRP Patch (PP)
Autologous PRP was prepared with the 2-stage centrifugation method and mixed with iohexol contrast. We chose two separate sites for epidural access. A standard epidural puncture was conducted under the guidance of CT. The PRP mixture was titrated slowly into the epidural space and must be stopped immediately to patient's perception of backache or irradiating pain. A strict bed stay for 48 h was prescribed in supine position postoperatively.
Aktiv komparator: Whole blood patch (WP)
Autologous whole blood was prepared and mixed with iohexol contrast. We chose two separate sites for epidural access. A standard epidural puncture was conducted under the guidance of CT. The whole blood mixture was titrated slowly into the epidural space and must be stopped immediately to patient's perception of backache or irradiating pain. A strict bed stay for 48 h was prescribed in supine position postoperatively.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
The complete relief rate of patients with SIH
Tidsram: At 3 months after first epidural patch
The complete relief was defined as the pain intensity of 0-1/10 on NRS or/and minimal symptoms post-procedurally.
At 3 months after first epidural patch

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Pain intensity of orthostatic headache
Tidsram: At 48 hours, 2 weeks, 3 and 6 months after first epidural patch
Pain intensity was evaluated by pain numeric rating scale (NRS; 0 = no pain, 10 = unbearable pain).
At 48 hours, 2 weeks, 3 and 6 months after first epidural patch
The complete relief rate of patients with SIH
Tidsram: At 48 hours, 2 weeks and 6 months after first epidural patch
The complete relief was defined as the pain intensity of 0-1/10 on NRS or/and minimal symptoms post-procedurally.
At 48 hours, 2 weeks and 6 months after first epidural patch
The good response rate of patients with SIH.
Tidsram: At 48 hours, 2 weeks, 3 and 6 months after first epidural patch
Good response was defined as a headache reduction of at least 50%, with improvement of orthostatic component post-procedurally.
At 48 hours, 2 weeks, 3 and 6 months after first epidural patch
The failure rate in each group.
Tidsram: At 6 months after first epidural patch
Failure was defined as a persistent or worsening symptom with less than 50% of headache reduction within 72 hour post-procedurally.
At 6 months after first epidural patch
The recurrence rate in each group.
Tidsram: At 6 months after first epidural patch
Recurrence was defined as fresh onset of orthostatic headache in completely relieved patients beyond the 72-hour mark.
At 6 months after first epidural patch
Patients'quality of life
Tidsram: At 3 and 6 months after first epidural patch
Patients'quality of life was evaluated by Headache Impact Test (HIT-6), with six item scores of headache-related disability divided into 36-49 (little or no impact), 50-55 (some impact), 56-59 (substantial impact), and ≥60 (severe impact).
At 3 and 6 months after first epidural patch
Patients' overall satisfaction
Tidsram: At 6 months after first epidural patch
Patients' overall satisfaction was graded into very unsatisfactory (1), unsatisfactory (2), neutral (3), satisfactory (4) and very satisfactory (5), according to the Likert scale.
At 6 months after first epidural patch
The occurrence of complications in each group.
Tidsram: During and after first epidural patch until the end of 6-month follow up.
During and after first epidural patch until the end of 6-month follow up.
The percent of patients requiring repeat epidural patch in each group
Tidsram: Within 6- month follow up
Within 6- month follow up

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 maj 2026

Primärt slutförande (Beräknad)

1 december 2028

Avslutad studie (Beräknad)

1 mars 2029

Studieregistreringsdatum

Först inskickad

16 maj 2026

Först inskickad som uppfyllde QC-kriterierna

16 maj 2026

Första postat (Faktisk)

22 maj 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

27 maj 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

22 maj 2026

Senast verifierad

1 maj 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • ky2023-263-03-09

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera